Mary Farr
Nurse Practitioner · Jacksonville, FLNPI 1861409419
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,433 of the $65,644 with a category attached, or 75.3%. Daiichi Sankyo Inc. accounts for 61.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $19,260 and has fallen 53.6% since, to $8,936 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $362.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$40K
- AstraZeneca$24K
- Novartis$181
- Seagen Inc.$134
- Johnson & Johnson$128
- Sanofi$114
- plus $575 from 18 others
What the payments were for
- Consulting fees$2,1003%
- Speaking & faculty fees$49,43375%
- Travel & lodging$9,52515%
- Food & beverage$4,5867%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 68 | $40,165 |
| AstraZeneca(2 entities) | 39 | $24,346 |
| Novartis | 10 | $181 |
| Seagen Inc. | 12 | $134 |
| Johnson & Johnson(2 entities) | 9 | $128 |
| Sanofi | 7 | $114 |
| Pfizer | 7 | $113 |
| Merck | 4 | $81 |
| Taiho Oncology, Inc. | 4 | $53 |
| AVEO Pharmaceuticals, Inc. | 3 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| AbbVie | 2 | $37 |
| Mirati Therapeutics, Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Legend Biotech USA Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Incyte Corporation | 1 | $13 |
| Myovant Sciences Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$58,698
How this compares
$65,644 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 19 | $313,733 |
| PiqrayAlpelisib | 13 | $287,265 |
| CalquenceAcalabrutinib Maleate | 12 | $277,966 |
| IbrancePalbociclib | 11 | $176,163 |
| Abiraterone Acetate | 13 | $36,501 |
| EliquisApixaban | 44 | $35,932 |
| XareltoRivaroxaban | 13 | $15,230 |
| ValacyclovirValacyclovir Hcl | 21 | $984 |
| Hydroxyurea | 29 | $791 |
| Tamoxifen Citrate | 12 | $644 |
| Anastrozole | 32 | $610 |
| Letrozole | 22 | $546 |
| Warfarin Sodium | 16 | $487 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 36 | $400 |
| Ondansetron Hcl | 33 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPiqray | $181 | $287,26513 claims |
| AstraZenecaCalquence | $24,346 | $277,96612 claims |
| PfizerIbrance, Eliquis | $113 | $212,09655 claims |
| Johnson & JohnsonXarelto | $128 | $15,23013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Jacksonville
- Stacey KellyJacksonville$22K
- Jean Sheridan-YoungJacksonville$22K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.